- Boehringer Ingelheim progresses to 6th place in the 2026 Access to Medicine Index
- Company performs above average across all three assessed areas, with significant progress in Governance of Access and Product Delivery
- Long-term health equity initiatives, partnerships, open innovation and stronger outcome measurement contribute to continued progress
Ingelheim, Germany - Boehringer Ingelheim has advanced to 6th place in the 2026 Access to Medicine Index (ATMI), continuing its rise from 13th in 2022 and 8th in 2024. This result recognizes the company's sustained progress to improving access to healthcare in low- and middle-income countries and reflects an approach that increasingly combines access to medicines with stronger health systems, local capabilities and research partnerships.
Every two years the ATMI evaluates the efforts of the world's leading pharmaceutical companies and ranks the top 20 based on their efforts to improve access to medicine in low- and middle-income countries. Boehringer performed above average across all three areas assessed by the Index, with particularly strong progress in Product Delivery, the area with the highest weighting. This reflects strong advancement of the company's approach to access, from expanding initiatives and long-term partnerships to open innovation and stronger impact measurements.
"Access to healthcare is not achieved through a single intervention. It requires long-term collaboration to strengthen research, healthcare capabilities, and enabling access to treatment in underserved communities, where significant gaps remain. Our progress in the ATMI is important recognition; however, what matters most is translating that progress into better health outcomes for more people," said Augusto Muench, Head of Sustainability at Boehringer.
Highlighted progress in this year's assessment includes:
- More comprehensive access strategies for cardio-renal-metabolic medicines, improving availability and affordability in low- and middle-income countries through approaches such as Access to Healthcare in Kenya.
- Long-term partnerships and capacity building initiatives in Sub-Saharan Africa, including the expanded partnership with the Botswana Vaccine Institute and support for social entrepreneurs and start-ups with focus on healthcare through business incubator and accelerator programs and impact investments.
- CRM Patient Africa, a long-term initiative launched in 2025 and currently underway in Kenya, Rwanda and Ghana, combining research capacity building, screening and diagnostics, healthcare professional trainings and efforts to support access to medicines.
- Growing global health initiatives, including Stop Rabies and Angels, continue to expand their reach. The Angels Initiative works together with ambulance crews, nurses, doctors, and hospitals to build stroke-ready networks and have reached over 28 million stroke patients to date.
- Open science through opnMe, strengthening R&D capacity through collaboration with academic researchers. Since the last assessment, research partners from countries covered by the Index have authored or co-authored over 15 new scientific publications.
- More robust outcome measurement supports stronger tracking and reporting and validates how access and health-system-strengthening initiatives are reaching more patients.
These achievements reflect the continued progress since Boehringer Ingelheim's strategic pivot towards health equity in 2023. “Expanding access is only part of the picture. We also need to understand whether our work is delivering meaningful and lasting change,” shared Dr. James Kinniburgh, global MORE HEALTH lead at Boehringer. Adding, “Stronger measurement gives us the evidence to better understand what works, lessons learned to strengthen our approach and ultimately, direct our efforts where they can make the biggest difference.”
As Boehringer Ingelheim continues to advance its health equity strategy and initiatives, the company reaffirms its commitment to meaningful collaboration with global health organizations, local partners, and underserved communities to support greater accessibility and affordability to healthcare, worldwide.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective. Our approximately 54,300 employees serve over 130 markets to build a healthier tomorrow. Learn more at www.boehringer-ingelheim.com.
About the Access to Medicine Index
The Access to Medicine Index analyses 20 of the largest research-based pharmaceutical companies with products for high-burden diseases in low- and middle-income countries. It ranks them on their efforts to improve access to medicine, identifies best practices, highlights where progress is being made and uncovers where critical action is still required. The Index is endorsed by over 145 investors, collectively managing assets worth over USD 22 trillion. It is published every two years by the Access to Medicine Foundation, an independent non-profit organisation funded by the Gates Foundation, the Leona M. and Harry B. Helmsley Charitable Trust, Wellcome Trust, UK Foreign, Commonwealth and Development Office and the Dutch Ministry of Foreign Affairs. Learn more: www.accesstomedicinefoundation.org
-
从车到船 共赢未来丨深圳科华携手产业伙伴共探全场景补能新机遇!水陆并进,向绿而行。今年,交通运输部等十一部门联合印发《推动新能源重卡规模化应用实施方案》,提出到2030年建设零碳公路运输通道3万公里;10月公开的2026-11-11
-
保诚冠名赞助「保诚保险香港冬日小镇.尖沙咀」点亮维港冬日保诚冠名赞助「保诚保险香港冬日小镇.尖沙咀」点亮维港冬日2026-11-11
-
国家级赛事管理系统启动! 海聊卫通旗下北斗之眼以北斗科技护航户外体育赛事10月15-18日,由中华全国体育总会主办的2026中国户外运动产业大会在北京市昌平区盛大举行。本届大会以“京彩户外 科创未来”为主题,汇聚户外运动产业各方力量,共同探2026-11-11
-
质量第一,信誉至上:安华仁药业的三十八年坚守与向"新"而行能穿越三十八年周期的企业,往往有独特的精神内核。北京安华仁药业有限公司自1988年成立以来,始终遵循"质量第一、信誉至上、科学管理、优质服务"的方针,并以"依2026-11-11
-
新罗酒店集团迎双十一购物季推出黑色星期五特别优惠,助力顾客提前规划2027年上半年旅行新罗会员专享客房优惠,部分客房产品优惠幅度可达28%,另有幸运抽奖及大韩航空合作礼遇 * 11月6日至19日,新罗会员可通过为期两周的黑色星期五促销活动,以专属优惠价格2026-11-11
-
AMD股价暴跌17%创近9年之最,苏姿丰紧急回应:AI增速远超想象
-
锚定健康中国新征程!第一届医药信息传播论坛将于广州启幕
-
Ledger 中国销售渠道说明:广州馨潇贸易有限公司官方直营渠道公示
-
江苏省脑机接口产业联盟在宁成立,麦澜德分享前沿成果
-
艾芬达入选国家知识产权强国建设示范创建对象:二十载长期主义,兑现每一份用户价值
-
Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
-
中荷人寿北京分公司成功举办中荷创享家品牌发布暨协同发展启航仪式
-
华为系具身智能公司具脑磐石完成新一轮融资:对标JEPA,押注类脑智能的认知世界模型
-
北京暑假补习班有哪些?家长首推一对一权威机构金博升学
-
上海高新技术企业代理机构深度访谈与推荐
